BERNS PAUL L — SEC insider filings
SEC reporting owner CIK 1202769. 27 insider filings on record with FilingPulse; latest filed 2026-11-05.
Transaction summary — filings shown
Covers all 27 filings on record, filed 2020-08-10 to 2026-11-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 5 filings — 6,049,350 shares, $89,719,941 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 7 legs across 5 filings — 30,762 shares, $1,104,016 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 53.
- Largest priced transaction: purchase of 2,321,262 shares @ $10.77 ($24,999,992) in Lyell Immunopharma, Inc., filed 2026-11-05.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | 10% owner | 2 | 2 legs · 2,809,352 sh · $37,499,977 | — | — |
| Kardigan, Inc. (KARD) | Director, 10% owner | 2 | 1 leg · 1,250,000 sh · $20,000,000 | — | 5 |
| Aspen Neuroscience, Inc. (ASPE) | 10% owner | 1 | 1 leg · 1,200,000 sh · $18,000,000 | — | — |
| Metsera, Inc. (MTSR) | Director | 3 | 1 leg · 789,998 sh · $14,219,964 | — | 11 |
| Jazz Pharmaceuticals plc (JAZZ) | Director | 3 | — | 5 legs · 7,072 sh · $1,046,089 | 4 |
| Neumora Therapeutics, Inc. (NMRA) | See Remarks, Director | 8 | — | 2 legs · 23,690 sh · $57,927 | 22 |
| EQRx, Inc. (EQRX) | Director | 4 | — | — | 7 |
| Unity Biotechnology, Inc. (UBX) | Director | 4 | — | — | 4 |
Insider filings — BERNS PAUL L
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-05 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN, NELSEN ROBERT, Burow Kristina, BYBEE CLINTON | Purchase (P): 2,321,262 @ $10.77 | EDGAR |
| 2026-11-02 | 4 | Aspen Neuroscience, Inc. (ASPE) jointly with ARCH Venture Partners XIV, L.P., ARCH Venture Partners XIV, LLC, ARCH Venture Fund XIV, L.P. | Purchase (P): 1,200,000 @ $15 | EDGAR |
| 2026-08-21 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Kardigan, Inc. (KARD) | Purchase (P): 1,250,000 @ $16 | EDGAR |
| 2026-06-22 | 4 | Kardigan, Inc. (KARD) | Conversion (C): 13,792,035 · Grant/award (A): 20,706 @ $0 · Conversion (C): 5,148,587 (derivative) · Conversion (C): 1,204,000 (derivative) · Conversion (C): 2,306,401 (derivative) | EDGAR |
| 2026-03-09 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN, BYBEE CLINTON | Purchase (P): 488,090 @ $25.61 | EDGAR |
| 2026-02-19 | 4 | Neumora Therapeutics, Inc. (NMRA) | Sale (S): 9,819 @ $3.51 | EDGAR |
| 2026-01-09 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 1,650,000 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | Metsera, Inc. (MTSR) | Disposition to issuer (D): 4,031 · Disposition to issuer (D): 7,523,682 · Disposition to issuer (D): 8,313,680 · Disposition to issuer (D): 957,559 · Grant/award (A): 4,031 (derivative) · Disposition to issuer (D): 24,188 (derivative) · +1 more | EDGAR |
| 2025-05-30 | 4 | Neumora Therapeutics, Inc. (NMRA) | Disposition to issuer (D): 497,049 (derivative) · Disposition to issuer (D): 955,864 (derivative) · Disposition to issuer (D): 342,500 (derivative) · Disposition to issuer (D): 2,000,000 (derivative) · Grant/award (A): 497,049 (derivative) · Grant/award (A): 955,864 (derivative) · +2 more | EDGAR |
| 2025-05-22 | 4 | Metsera, Inc. (MTSR) | Grant/award (A): 24,188 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Neumora Therapeutics, Inc. (NMRA) | Sale (S): 13,871 @ $1.69 | EDGAR |
| 2025-02-18 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 2,000,000 (derivative) @ $0 · Disposition to issuer (D): 497,049 (derivative) · Disposition to issuer (D): 955,864 (derivative) · Disposition to issuer (D): 342,500 (derivative) · Grant/award (A): 497,049 (derivative) · Grant/award (A): 955,864 (derivative) · +1 more | EDGAR |
| 2025-02-03 | 4 | Metsera, Inc. (MTSR) | Conversion (C): 7,523,682 · Purchase (P): 789,998 @ $18 · Conversion (C): 15,000,000 (derivative) · Conversion (C): 2,678,571 (derivative) | EDGAR |
| 2024-12-27 | 4 | Neumora Therapeutics, Inc. (NMRA) | Gift (G): 133,097 @ $0 · Gift (G): 133,097 @ $0 · Gift (G): 133,097 @ $0 | EDGAR |
| 2024-06-21 | 4 | Unity Biotechnology, Inc. (UBX) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 171,250 @ $0 · Grant/award (A): 342,500 (derivative) @ $0 | EDGAR |
| 2023-11-09 | 4 | EQRx, Inc. (EQRX) | Disposition to issuer (D): 627,000 · Disposition to issuer (D): 101,010 (derivative) @ $0 · Disposition to issuer (D): 86,344 (derivative) | EDGAR |
| 2023-06-26 | 4 | Unity Biotechnology, Inc. (UBX) | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2023-01-04 | 4 | EQRx, Inc. (EQRX) | Grant/award (A): 453 (derivative) | EDGAR |
| 2022-10-04 | 4 | EQRx, Inc. (EQRX) | Grant/award (A): 101,010 (derivative) @ $0 | EDGAR |
| 2022-06-27 | 4 | Unity Biotechnology, Inc. (UBX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-12-21 | 4 | EQRx, Inc. (EQRX) | Grant/award (A): 627,000 · Grant/award (A): 85,891 (derivative) | EDGAR |
| 2021-08-09 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Sale (S): 1,450 @ $154 | EDGAR |
| 2021-06-28 | 4 | Unity Biotechnology, Inc. (UBX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2020-11-04 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Option exercise (M): 4,691 · Sale (S): 466 @ $147.44 · Sale (S): 400 @ $149.28 · Sale (S): 3,825 @ $150.90 · Option exercise (M): 4,691 (derivative) | EDGAR |
| 2020-08-10 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 2,705 @ $0 · Sale (S): 931 @ $125.87 · Grant/award (A): 6,765 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1202769 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs